Written Question·Department of Health and Social Care·UIN 48753
Multiple Sclerosis: Drugs
Tabled: 28 April 2025
Answered: 12 May 2025
Named DayQuestion
Laurence Turner
Labour — Birmingham Northfield
To ask the Secretary of State for Health and Social Care, whether (a) his Department, (b) his Department's agencies and (c) his Department's advisory bodies have made comparative assessments of the efficacy of (i) natalizumab Tysabri and (ii) natalizumab
Answer
Karin SmythTyruko and Tysabri are United Kingdom licensed medicines. Tyruko is a biosimilar to the originator Tysabri. A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorised original biological medicin...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 48753) →